CLINICAL TRIALS PROFILE FOR CLOFIBRATE
✉ Email this page to a colleague
All Clinical Trials for CLOFIBRATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000482 ↗ | Coronary Drug Project | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1965-04-01 | To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction. |
| NCT00000483 ↗ | Coronary Drug Project Mortality Surveillance | Completed | National Heart, Lung, and Blood Institute (NHLBI) | N/A | 1981-06-01 | To determine whether there were any long term sequelae of the drugs used in the Coronary Drug Project (estrogens, dextrothyroxine, nicotinic acid, clofibrate). |
| NCT00238004 ↗ | The Low HDL On Six Weeks Statin Therapy (LOW) Study | Unknown status | Craigavon Area Hospital | Phase 4 | 2005-11-01 | Abnormal blood cholesterol levels increase the risk of developing, or dying from heart disease. It is well recognised that if "harmful" LDL cholesterol is high, and "protective" HDL cholesterol is low, this risk is increased. Drugs called statins are routinely used in patients with heart disease, are well tolerated, and decrease the harmful LDL cholesterol levels. However, statins only increase protective HDL cholesterol to a small extent. Some patients may thus benefit from additional medication to increase protective HDL-cholesterol further. One of the most effective drugs which can do this is nicotinic acid. This drug is well established having been available for over 30 years. Previous use has been limited by facial flushing in a large percentage of patients receiving the drug. However a new formulation called Niaspan is now available which is associated with much less flushing. Although many patients will have transient flushing, it is estimated that only 1 patient out of every 20 receiving the drug will have to discontinue treatment. We therefore propose, in patients with coronary artery disease and low HDL cholesterol despite being on a statin, to study the effect of Niaspan on HDL cholesterol and other lipid parameters, and to assess its tolerability. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CLOFIBRATE
Condition Name
Clinical Trial Locations for CLOFIBRATE
Trials by Country
Clinical Trial Progress for CLOFIBRATE
Clinical Trial Phase
Clinical Trial Sponsors for CLOFIBRATE
Sponsor Name
